Multimodality therapy for the treatment of muscle-invasive bladder cancer

Seminars in Urologic Oncology

Volumn 18, Issue 4, 2000, Pages 313-322

  Thurman, S A ^a   DeWeese, T L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bladder cancer; Organ preservation; Radiation therapy

Indexed keywords

CISPLATIN; METHOTREXATE; VINBLASTINE;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER SURVIVAL; CYSTECTOMY; DRUG INDUCED DISEASE; HUMAN; ORGAN PRESERVATION; PRIORITY JOURNAL; REVIEW; URINARY DIVERSION;

COMBINED MODALITY THERAPY; HUMANS; NEOPLASM INVASIVENESS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER NEOPLASMS;

EID: 0033694919     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Cancer Statistics 2000
2. Cancer of the bladder
3. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy
4. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: Interim report on radiation therapy oncology group study No. 83-14
5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer
6. Reanalysis and results after 12 years of follow up in a randomized clinical trial comparing total mastectomy with lumpectomy with and without irradiation in the treatment of breast cancer
7. Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data
8. Treatment of advanced bladder cancer category T2 T3 and T4a
9. Selective bladder preservation by combination treatment of invasive bladder cancer
10. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: A prospective study
11. Bladder preservation by combined modality therapy for invasive bladder cancer
12. Neo-adjuvant chemotherapy for invasive bladder cancer: Experience with the M-VAC regimen
13. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study
14. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma: A single institution phase II study
15. Organ sparing treatment of advanced bladder cancer: A 10 year experience
16. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy
17. Initial results of RTOG 95-06: A phase I/II trial of transurethral surgery and fractionated twice daily radiation with concurrent cisplatin and 5-fluorouracil followed either by selective bladder preservation or cystectomy for patients with muscle invading bladder cancer
18. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle invasive carcinoma of the urinary bladder
19. Phase II trial of combination paclitaxel and cispolatin in advanced urothelial carcinoma
20. Response to a taxol based chemotherapy regimen in advanced transitional cell carcinoma is independent of p53 expression
21. Phase I evaluation of sequential doxorubicin and gemcitabine then ifosfamide and paclitaxel and cisplatin for patients with unresectable or metastatic transitional cell carcinoma
22. Phase II trial of palitaxel, cisplatin and gemcitabine in patients with advanced transitional cell carcinoma of the urotheltum
23. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of radiation therapy oncology groups phase II trial 88-02
24. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation
25. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of radiation therapy oncology group 89-03
26. In reply. Correspondance
27. The kock ileal neobladder: Updated experience in 295 male patients
28. Orthotopic ileocolic neobladder reconstruction following radical cystectomy: History, technique and results of the Johns Hopkins experience, 1986-1998
29. Sexual function following radical radiotherapy for bladder cancer
30. Neuroanatomical approach to radical cystoprostatectomy with reservation of sexual function
31. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer
32. Muscle-invasive bladder cancer treated with external beam radiotherapy: Prognostic factors
33. The combination of cis-platin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder
34. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy
35. Apoptosis, proliferation and p53, cyclin D1 and retinoblastoma gene expression in relation to radiation response in muscle invasive bladder cancer
36. Apoptosis, p53, Bcl-2 and Ki-67 in invasive bladder cancer: Possible predictors of successful bladder preservation following transurethral resection and radiochemotherapy
37. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer
38. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle invasive bladder cancer
39. DNA analysis in predicting survival of irradiated patients with transitional cell carcinoma of the bladder
40. Combined intraarterial chemotherapy and radiotherapy in the treatment of bladder carcinoma
41. Radiation therapy and concurrent daily intra-arterial infusion of low dose cisplatin following alteration of pelvic blood flow for invasive bladder cancer: A preliminary report
42. Phase I trial of intravesical administration of recombinant human interleukin-12 for superficial transitional cell bladder tumors
43. Targeting superficial bladder cancer by the intravesical administration of copper-67 labeled anti-MUC1 mucin monoclonal antibody C595
44. Preclinical evaluation of copper-67 labeled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer
45. Potential clinical efficacy of intensity-modulated conformal therapy